REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	10/517,805			
Filing Date	December 05, 2005			
First Named Inventor	Ernesto MENTA 1625			
Art Unit				
Examiner Name	DENTZ, Bernard I.			
Attorney Docket Number	200144.413USPC			

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1.	Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant natructs otherwise. If applicant does not wish to have any previously filed unentered amendment(e) entered, applicant must exquest non-entry of such amendment(e) entered, applicant must exquest non-entry of such amendment(e).										
	 a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. 										
	i.	<u> </u>									
	ii.	Other									
	ь. 🔀 i.	Enclo	sea endment/Reply			iii.	□Informo	tion Disclosure Statement (IDS)			
	ii	=	davit(s)/Declara	tion(s)		iv.	Other_				
2.	Misce	scellaneous									
	а. 🗌	Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)									
	b. 🗌	Other									
3.	Fees	The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.									
	a. 🛚	The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 031182 (Cell Therapeutics – Assignee).									
	i.	RCE fee required under 37 CFR 1.17(e)									
	ii.	Extension of time fee (37 CFR 1.136 and 1.17)									
	iii.										
	b.	Check in the amount of \$ enclosed									
	c. 📋										
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.											
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED											
			12 mes	J. Male		D-4-		April 7, 2009			